336 related articles for article (PubMed ID: 35177901)
1. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
2. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
3. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
4. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting.
Bogart M; Glassberg MB; Reinsch T; Stanford RH
Respir Med; 2018 Dec; 145():138-144. PubMed ID: 30509702
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
Bengtson LGS; DePietro M; McPheeters J; Fox KM
Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
[TBL] [Abstract][Full Text] [Related]
6. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study.
Strange C; Tkacz J; Schinkel J; Lewing B; Agatep B; Swisher S; Patel S; Edwards D; Touchette DR; Portillo E; Feigler N; Pollack M
Int J Chron Obstruct Pulmon Dis; 2023; 18():2245-2256. PubMed ID: 37849918
[TBL] [Abstract][Full Text] [Related]
7. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
8. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
[TBL] [Abstract][Full Text] [Related]
9. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
[TBL] [Abstract][Full Text] [Related]
11. Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.
Czira A; Akiyama S; Ishii T; Wood RP; Camidge LJ; Wallis H; Jennison T; Wild RAC; Yarita M; Hashimoto K; Rothnie KJ; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():2933-2953. PubMed ID: 38089540
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Triple Therapy Treatment Pathways in Chronic Obstructive Pulmonary Disease (COPD): A Machine-Learning Predictive Model.
Bogart M; Liu Y; Oakland T; Stiegler M
Int J Chron Obstruct Pulmon Dis; 2022; 17():735-747. PubMed ID: 35418750
[TBL] [Abstract][Full Text] [Related]
13. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
15. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
19. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]